Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM5 | P08912 | 1/20 | 0.53 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21026134 | 0.85 | CHRM5 (0.53) | CHRM5CHRM3SIGMAR1ALDH1A1HTT | |
| SCHEMBL2629206 | 0.84 | SIGMAR1 (0.66) | CHRM5CHRM3SIGMAR1ALDH1A1POLB | |
| SCHEMBL20231296 | 0.83 | SIGMAR1 (0.48) | SIGMAR1ALDH1A1KDM4E | |
| SCHEMBL21472815 | 0.80 | SIGMAR1 (0.51) | CHRM5CHRM3SIGMAR1ALDH1A1HTT | |
| SCHEMBL23095532 | 0.80 | SIGMAR1 (0.74) | CHRM5CHRM3SIGMAR1ALDH1A1POLB | |
| SCHEMBL7720993 | 0.78 | CHRM5 (0.62) | CHRM5CHRM3SIGMAR1ALDH1A1HTT | |
| SCHEMBL23862112 | 0.78 | CHRM5 (0.62) | CHRM5CHRM3ALDH1A1HTTPOLB | |
| SCHEMBL6478473 | 0.78 | ITGB3 (0.50) | SIGMAR1ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL12774048 | 0.77 | SMN1; SMN2 (0.45) | SIGMAR1ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL23464917 | 0.77 | CHRM5 (0.75) | CHRM5CHRM3SIGMAR1ALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11161841-B2 | Modulators of proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2021-11-02 | — | — | US | disclosed |
| US-20190315732-A1 | MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2019-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190315732-A1 | MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | MDM2, CRBN, VHL | CHRM5 4497/4885CHRM3 4695/4885SIGMAR1 4148/4885 |
| US-11161841-B2 | Modulators of proteolysis and associated methods of use | MDM2, CRBN, VHL | CHRM5 4497/4885CHRM3 4695/4885SIGMAR1 4148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.